Trials / Conditions / Enteropathy-Associated T-Cell Lymphoma

Enteropathy-Associated T-Cell Lymphoma

19 registered clinical trials studyying Enteropathy-Associated T-Cell Lymphoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Exp NCT07055477	National Cancer Institute (NCI)	Phase 1
Withdrawn	Tazemetostat Plus CHOP in 1L T-cell Lymphoma NCT06692452	Eric Jacobsen, MD	Phase 2
Not Yet Recruiting	Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients NCT06701344	Ruijin Hospital	Phase 2
Active Not Recruiting	Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T- NCT05377827	Washington University School of Medicine	Phase 1
Recruiting	A Registry for People With T-cell Lymphoma NCT05978141	Memorial Sloan Kettering Cancer Center	—
Withdrawn	Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma NCT04639843	National Cancer Institute (NCI)	Phase 1
Recruiting	A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas NCT05475925	Dren Bio	Phase 1 / Phase 2
Suspended	Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma NCT04803201	Alliance for Clinical Trials in Oncology	Phase 2
Unknown	CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Labe NCT04480788	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	Phase 1
Completed	CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Ty NCT03217643	Imagine Institute	Phase 2
Active Not Recruiting	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lym NCT03113500	City of Hope Medical Center	Phase 2
Completed	T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas NCT03049449	National Cancer Institute (NCI)	Phase 1
Completed	A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymp NCT02588651	Deepa Jagadeesh	Phase 2
Completed	Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715	Mayo Clinic	N/A
Unknown	CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL NCT02533700	Shandong Provincial Hospital	Phase 2
Active Not Recruiting	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency NCT01787409	Mayo Clinic	N/A
Unknown	CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymph NCT01746992	Ruijin Hospital	Phase 4
Unknown	CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study NCT01719835	Royal Marsden NHS Foundation Trust	Phase 2
Completed	Study of MLN8237 in Participants With Advanced Hematological Malignancies NCT00697346	Millennium Pharmaceuticals, Inc.	Phase 1